Journal of Cytokine Biology
Open Access

Marina A. Dobrovolskaia

Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA

Biography

Dr. Marina A. Dobrovolskaia is Laboratory co-Director, Director of Operations and the Head of Immunology Section at the Nanotechnology Characterization Laboratory (NCL).  In her role as the Director of Operations, Dr. Dobrovolskaia leads the NCL operations to provide preclinical nanoparticle characterization services to the nanotechnology research community, advance the translation of promising nanotechnology concepts from bench to the clinic, and contribute to the education of the next generation of scientists in the field of preclinical development of nanotechnology-based products, the activities emphasized in the NCL mission.

Publications

Chemical Modification of CRISPR gRNAs Eliminate type I Interferon Responses in Human Peripheral Blood Mononuclear Cells

Objectives: CRISPR/Cas9 is currently the primary tool used for genome editing in mammalian cells. To cleave and alter genomic DNA, both the Cas9 nuclease and a guide RNA (gRNA) must be present in the nucleus. One preferred method of introducing these reagents is direct transfection of a recombinant Cas9 protein complexed with a synthetic gRNA as a ... Read More»

Mollie S. Schubert, Edward Cedrone, Barry Neun, Mark A. Behlke and Marina A. Dobrovolskaia

Case Report: J Cytokine Biol, 3: 121

DOI: 10.4172/2576-3881.1000121

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article